Risks and benefits of activated protein C treatment for severe sepsis

New England Journal of Medicine

Volumn 347, Issue 13, 2002, Pages 1027-1030

  Warren, H Shaw ^a   Suffredini, Anthony F ^a   Eichacker, Peter Q ^a   Munford, Robert S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; DROTRECOGIN;

ARTICLE; BLEEDING; CLINICAL TRIAL; DISEASE SEVERITY; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INTENSIVE CARE; MORTALITY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SEPSIS;

ANTI-INFECTIVE AGENTS; APACHE; CLINICAL TRIALS; DRUG APPROVAL; HEMORRHAGE; HUMANS; PROTEIN C; RECOMBINANT PROTEINS; RISK; SEPSIS; UNITED STATES;

EID: 0037179685     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMsb020574     Document Type: Article

References (13)

1. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient: high-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-78. [Erratum, JAMA 2002;287:192.]
2. Chiron announces results of phase III study of tifacogin in severe sepsis. Emeryville, Calif.: Chiron, 2001. (Accessed September 6, 2002, at http:// www.chiron.com.)
3. Bernard GR, Vincent J·L, Laterre P-F, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
4. Anti-Infective Advisory Committee. FDA briefing document: drotrecogin alfa (activated) [recombinant human activated protein C (rhAPC)] Xigris, BLA#125029/0. Rockville, Md.: Food and Drug Administration, September 12, 2001. (Accessed September 6, 2002, at http://www.fda.gov/ ohrms/dockets/ac/01/briefing/3797b1_02_FDAbriefing.doc.)
5. CDER 2001 meeting documents. Rockville, Md.: FDA Dockets Management Branch, 2001. (Accessed September 6, 2002, at http://www.fda. gov/ohrms/dockets/ac/cder01.htm#Anti-Infective.)
6. Yan SC, Razzano P, Chao YB, et al. Characterization and novel purification of recombinant human protein C from three mammalian cell lines. Biotechnology (N Y) 1990;8:655-61.
7. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
8. Polderman KH, Christiaans HM, Wester JP, Spijkstra JJ, Girbes AR. Intra-observer variability in APACHE II scoring. Intensive Care Med 2001; 27:1550-2.
9. Polderman KH, Jorna EM, Girbes AR. Inter-observer variability in APACHE II scoring: effect of strict guidelines and training. Intensive Care Med 2001;27:1365-9.
10. CBER. Biologics license application: recombinant human activated protein C (rhAPC) [drotrecogin alfa (activated)] Xigris for severe sepsis. Rockville, Md.: Food and Drug Administration, October 2001. (Accessed September 6, 2002, at http://www.fda.gov/ohrms/dockets/ac/01/slides/3797s1_02_forsyth/.)
11. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987;79:918-25.
12. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997;25:1095-100.
13. Natanson C, Esposito CJ, Banks SM. The siren's songs of confirmatory sepsis trials: selection bias and sampling error. Crit Care Med 1998;26: 1927-30.